

•

5

- 35

11. The method of claim 1, wherein the complex is administered by injection.

12. The method of claim 11, wherein the complex is administered intravenously.

13. A method for treating liver cancer in a subject comprising, administering to the subject a complex comprising a portion which specifically binds Fc α RI expressed on liver cells, or which specifically binds monomeric IgA or the Fc region thereof, linked to a cytotoxin.

14. The method of claim 13, wherein the portion which binds Fc α RI comprises monomeric IgA or the Fc region thereof.

15. The method of claim 13, wherein the portion that binds Fc α RI comprises an antibody or antibody fragment.

16. The method of claim 15, wherein the antibody is a human or humanized antibody.

17. The method of claim 11, further comprising administering to the subject a cytokine which increases expression of Fc α RI on the liver cells.

18. The method of claim 17, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 β , IL-8, and TNF- α .

19. A method for treating or preventing septicemia in a subject comprising administering to the subject a complex comprising a portion which specifically binds Fc α RI expressed on liver cells, or which specifically binds monomeric IgA or the Fc region thereof, linked to a cytotoxin.

20. The method of claim 19, wherein the portion which Fc α RI comprises monomeric IgA or the Fc region thereof.

21. The method of claim 19, wherein the portion that binds Fc α RI comprises an antibody or antibody fragment.

- 24 -

22. The method of claim 21, wherein the antibody is a human or humanized antibody.

23. The method of claim 19, further comprising administering to the
5 subject a cytokine which increases expression of Fc α RI on the liver cells.

24. The method of claim 23, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 β , IL-8, and TNF- α .

10/22/00 16:00:28